Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease

PartnershipSGK1 InhibitorPositive

AI Analysis

Summary

Thryv Therapeutics has secured an exclusive worldwide license for a new class of SGK1 inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, expanding its platform into neurodegenerative and cardiovascular indications including Parkinson's and Alzheimer's disease.

Importance:6/10

Sentiment:

0.60

licensingpartnershipSGK1 inhibitorneurodegenerative diseaseParkinson's diseaseAlzheimer's diseaseplatform expansion

Related Companies

$INTI

Read the original article

Published by PR Newswire Clinical Trials on September 3, 2026 8:23 PM

Read Original